Roche’s POL7080 Polyphor Pact Signals Re-Entry Into Antibiotics R&D
This article was originally published in The Pink Sheet Daily
By choosing Switzerland-based Polyphor’s investigational macrocycle antibiotic POL7080 for development and commercialization, Roche has given notice that it’s back in the antimicrobials space again.
You may also be interested in...
With BIO 2012 taking place June 17-21, the entire health care world awaits the Supreme Court’s ruling on health care reform. In the pharma world, companies are strategizing against all the possible outcomes.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.